title: Azacitidine in AML: a treatment option?
abstract: In this issue of Blood, Dombret et al report the final analysis of the international phase 3 study of azacitidine vs conventional care regimens in older (≥65 years), newly diagnosed acute myeloid leukemia (AML) patients with >30% bone marrow blasts and white blood cell (WBC) counts ≤15 × 109/L (AZA-AML-001 study).
authors.affiliation: RADBOUD UNIVERSITY MEDICAL CENTER.
authors.forename: Gerwin
authors.initials: G
authors.lastname: Huls
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use*; D001752:Blast Crisis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality*; D008297:Male
chemical_list: D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine